DNLI250117P20000
- 1.80
- 0.000.00%
Denali Therapeutics Newsroom
Why Denali Therapeutics (DNLI) Is the Biotech Stock With Biggest Upside Potential
BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $32
BTIG Keeps Their Buy Rating on Denali Therapeutics (DNLI)
Why Is Denali Therapeutics Stock Trading Higher On Wednesday?
TD Cowen Maintains Denali Therapeutics(DNLI.US) With Buy Rating
Denali Therapeutics (DNLI) Receives a Buy From TD Cowen
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $30
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $41
Denali Therapeutics: Strategic Advancements and Financial Strength Justify Buy Rating
Express News | Denali Therapeutics Inc: Anticipates Its Cash Runway Will Extend Into 2028
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
Have Denali Therapeutics Insiders Been Selling Stock?
Insider Sale: Chief Medical Officer of $DNLI (DNLI) Sells 2,907 Shares
Denali Therapeutics Receives FDA Breakthrough Therapy Designation For Tividenofusp Alfa In Treatment Of Hunter Syndrome (MPS II)
Express News | Denali Therapeutics Inc - Expects to Submit Bla for Tividenofusp Alfa in Early 2025
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics Is Maintained at Overweight by JP Morgan
Denali's ALS Study Fails to Meet Primary and Secondary Endpoints
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali Therapeutics: Strategic Pipeline Potential and Investment Opportunity Amid Recent Setbacks